# Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study

> **NCT02614196** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 986 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Galcanezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02614196
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-04
- **Primary completion:** 2017-03-29
- **Final completion:** 2018-10-05
- **Target enrollment:** 986 (ACTUAL)
- **Last updated:** 2020-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02614196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02614196, "Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02614196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*